Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm

Table 2 Comparison of contrast-enhanced ultrasound characteristics between hepatic neuroendocrine neoplasm group and hepatocellular carcinoma group, n (%)

Contrast-enhanced Ultrasound characteristics		hNEN group, n = 55	HCC group, n = 55	t/χ2	P value
Initial enhancement time in s		16.23 ± 5.29	16.52 ± 5.17	0.291	0.772
Washout to iso-enhancement time in s		26.91 ± 15.39	47.26 ± 16.84	6.615	0.000
Washout to hypo-enhancement time in s		59.84 ± 37.91	99.63 ± 61.82	5.092	0.000
Enhancement level at arterial phase	High	53 (96.4)	55 (100)	2.037	0.154
	Equal	2 (3.6)	0 (0)
	Low	0 (0)	0 (0)
Enhancement level at portal venous phase	Equal	7 (12.7)	11 (20.0)	1.063	0.303
	Low	48 (87.3)	44 (80.0)
Enhancement level at late phase	Equal	2 (3.6)	1 (1.8)	0.343	0.558
	Low	53 (96.4)	54 (98.2)
Enhancement forms	Fast forward and fast out	53 (96.4)	51 (92.8)	0.705	0.401
	Equal/slow forward and fast out	2 (3.6)	4 (7.2)
Enhancement forms	Uniform	33 (60)	39 (70.9)	1.447	0.229
	Non-uniform	22 (40)	16 (29.1)
Tumor vasculature	Yes	34 (61.8)	38 (69.1)	0.643	0.423
	No	21 (38.2)	17 (30.9)
Tumor necrosis	Yes	16 (29.1)	19 (34.5)	0.377	0.539
	No	39 (70.9)	36 (65.5)
Capsule enhancement	Yes	7 (12.7)	2 (3.6)	3.025	0.082
	No	48 (87.3)	53 (96.4)

hNEN: Hepatic neuroendocrine neoplasm; HCC: Hepatocellular carcinoma.